An $84,000 hepatitis drug called Sovaldi is at the center of a new battle between pharmaceutical companies and insurers — but the fight is about much more than one drug.
Sovaldi costs $1,000 per day, or $84,000 for a full treatment, and cures 90 percent of hepatitis C patients who take it. Insurers say the drug is ridiculously overpriced; the pharmaceutical industry says it’s a steal.
But the debate here isn’t simply about one hepatitis drug. Sovaldi is more like a single skirmish that has reawakened a broader, deeper, and higher-stakes cold war over the cost of prescription drugs. Officials in both industries say that even if Sovaldi’s manufacturer, Gilead, slashed its prices, the newly intensified battle between insurers and pharma companies wouldn’t recede: Sovaldi is just the beginning.
Sovaldi is a lightning rod because insurers and consumer advocates are afraid it’s a sign of what’s to come. The drug pipeline is full of drugs like Sovaldi, and insurers say that flood of new, expensive products will cause health care spending to skyrocket.
“I think that this one drug is the canary in the coal mine. It’s one that is out front and one of the first ones we’re seeing, but there are a lot more down the pipeline,” said Brendan Buck, a spokesman for America’s Health Insurance Plans.
Until Sovaldi, the class of products known as “specialty drugs” was mainly tailored to relatively rare conditions. The drugs are complex, which makes them more expensive to produce, driving up the price for consumers. And because they treat rarer conditions, there were fewer potential customers — another factor driving up prices.
Specialty drugs have always been expensive. They account for roughly 25 percent of U.S. spending on prescription drugs, but just 1 percent of all prescriptions, according to a newly formed coalition lobbying for lower prices.
But Sovaldi set off a particular shock wave largely because it treats a more common ailment — some 3 million people have hepatitis C. They can’t all afford an $84,000 course of treatment, but still, critics argue, the drug’s large potential customer base means that a once-narrow slice of drug spending could explode.
“If this sets a pattern for other drugs then we’re really in deep trouble “¦ it’s the combination of the price and the volume,” said John Rother, who helped start the Coalition for Sustainable Rx Pricing. The new organization, which also includes AARP and other health care advocates, launched Wednesday.
The pharmaceutical industry says critics are missing the point. Yes, Sovaldi is expensive, it argues, but that’s because it works. Sovaldi cures about 90 percent of patients with a common form of hepatitis C within its 12-week course.
Spending $84,000 on a cure might seem expensive up front, but it’s a lot more efficient in the long run than paying for a string of less effective treatments, including hospitalizations that run the risk of complications, the drug industry says.
A report from Optum, a consulting subsidiary of United Healthcare, agrees. Even very expensive drugs can be cost-effective if they work well enough, Optum said in a report issued before Sovaldi’s price was released.
“It is certainly possible that the combination of higher cure rates and reduced side effects, combined with reduced treatment times, may mean even greater cost-effectiveness in the future,” Optum’s analysts wrote.
A pharmaceutical industry official said insurers’ effort to crack down on Sovaldi and other specialty drugs is short-sighted. The insurance industry is under tremendous pressure to keep premiums low, especially in the first few years of Obamacare enrollment, and it’s reacting to that pressure by steering health providers and consumers away from products that are more expensive in the short term, the official said — but is running the risk of foregoing longer-term savings.
The basic dynamics underneath this tension are nothing new: Pharmaceutical companies want insurers to cover their drugs, which helps them make money; insurers want to avoid shelling out tens of thousands of dollars for expensive treatments, which helps them make money.
But the Sovaldi dust-up has turned up the intensity, as insurers make an aggressive case that they’re not the ones to blame if rising health care costs drive up premiums.
“The reality is that the company in this case is asking for a blank check, and we can’t give anyone a blank check in the health care system “¦ because it will blow up family budgets, it will blow up state Medicaid budgets, it will blow up employer benefit costs, and it will wreak havoc on the federal debt,” AHIP President and CEO Karen Ignagni said at a recent event sponsored by The Atlantic.
- 1 The Gender Politics of Pence’s Governor Pick
- 2 Trump gets bounce from convention and now it’s Clinton’s turn
- 3 On Convention’s First Night, Bernie Sanders and His Supporters Upstage Clinton
- 4 Can Hillary Clinton Succeed on the Hill Where Obama Didn’t?
- 5 Congress’ Inaction On Zika Funding Could Cost The U.S. More In the Long Run
What We're Following See More »
Instead of his usual stump speech, Bernie Sanders tonight threw his support behind Hillary Clinton, providing a clear contrast between Clinton and GOP nominee Donald Trump on the many issues he used to discuss in his campaign stump speeches. Sanders spoke glowingly about the presumptive Democratic nominee, lauding her work as first lady and as a strong advocate for women and the poor. “We need leadership in this country which will improve the lives of working families, the children, the elderly, the sick and the poor,” he said. “Hillary Clinton will make a great president, and I am proud to stand with her tonight."
In a stark contrast from Michelle Obama's uplifting speech, Massachusetts Senator Elizabeth Warren spoke about the rigged system plaguing Americans before launching into a full-throated rebuke of GOP nominee Donald Trump. Trump is "a man who has never sacrificed anything for anyone," she claimed, before saying he "must never be president of the United States." She called him divisive and selfish, and said the American people won't accept his "hate-filled America." In addition to Trump, Warren went after the Republican Party as a whole. "To Republicans in Congress who said no, this November the American people are coming for you," she said.
"In this election, and every election, it's about who will have the power to shape our children for the next four or eight years of their lives," Michelle Obama said. "There is only one person who I trust with that responsibility … and that is our friend Hillary Clinton." In a personal and emotional speech, Michelle Obama spoke about the effect that angry oppositional rhetoric had on her children and how she chose to raise them. "When they go low, we go high," Obama said she told her children about dealing with bullies. Obama stayed mostly positive, but still offered a firm rebuke of Donald Trump, despite never once uttering his name. "The issues a president faces cannot be boiled down to 140 characters," she said.
Many Bernie Sanders delegates have spent much of the first day of the Democratic National Convention resisting unity, booing at mentions of Hillary Clinton and often chanting "Bernie! Bernie!" Well, one of the most outspoken Bernie Sanders supporters just told them to take a seat. "To the Bernie-or-bust people: You're being ridiculous," said comedian Sarah Silverman in a brief appearance at the Convention, minutes after saying that she would proudly support Hillary Clinton for president.
The Democratic National Committee issued a formal apology to Bernie Sanders today, after leaked emails showed staffers trying to sabotage his presidential bid. "On behalf of everyone at the DNC, we want to offer a deep and sincere apology to Senator Sanders, his supporters, and the entire Democratic Party for the inexcusable remarks made over email," DNC officials said in the statement. "These comments do not reflect the values of the DNC or our steadfast commitment to neutrality during the nominating process. The DNC does not—and will not—tolerate disrespectful language exhibited toward our candidates."